
Opinion|Videos|December 23, 2025
Highlighting Other Uveal Melanoma Data From ESMO 2025 and Beyond
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), break down other data in metastatic uveal melanoma from the 2025 ESMO Congress.
Advertisement
Episodes in this series

Prof.Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), highlight key metastatic uveal melanoma findings presented at the 2025 ESMO Congress, including updates on systemic immunotherapies and novel targeted agents. They discuss how these data contribute to a growing evidence base supporting more personalized treatment strategies. Dr. Forschner and Dr. Khan also point out early-phase signals and emerging mechanisms that may influence therapeutic development in the coming years.
Advertisement
Related to this article

The FDA granted fast track designation to elticertinib for pretreated EGFR exon 20 insertion–mutated NSCLC.

Phase 2 NB2012 data showed a 3-year event-free survival rate of 73.7% with daretabart plus induction chemotherapy.

Deepa Rangachari, MD, discusses community oncology training, goal-concordant mentorship, genomic fluency, and multidisciplinary care.

Mayo Clinic researchers identified BRCA2 variants linked to moderate breast cancer risk, potentially informing personalized screening and prevention.

Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.

Maintenance galinpepimut-S extended overall survival in transplant-ineligible AML in second or later remission.

Longer follow-up of KANDLELIT-001 supports frontline calderasib plus pembrolizumab in KRAS G12C–mutated metastatic non–small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
2
Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC
3
Galinpepimut-S Improves OS in AML in Second or Later Remission
4
ESMO 2026 Data Highlight ADC Activity in Brain Metastases and TNBC
5

